Tech Company Financing Transactions
Aerie Pharmaceuticals Funding Round
On 10/12/2005, Aerie Pharmaceuticals received $21 million in Series A financing from Alta Partners and TPG Capital.
Transaction Overview
Company Name
Announced On
10/12/2005
Transaction Type
Venture Equity
Amount
$21,000,000
Round
Series A
Investors
Alta Partners (Lead Investor) (David Mack)
TPG Capital (Geoff Duyk)
Proceeds Purpose
In addition to the initial candidate, Aerie will also pursue development of a proprietary, breakthrough class of glaucoma product that incorporates novel chemistry to improve penetration of drugs into the eye.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4301 Emperor Blvd. 400
Durham, NC 27703
USA
Durham, NC 27703
USA
Phone
Website
Email Address
Overview
Aerie Pharmaceuticals is focused on developing products for the pharmaceutical treatment of glaucoma.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Vicente Anido
Chief Financial Officer
Richard Rubino
Chief Medical Officer
Richard Lewis
Chief Scientific Officer
Casey Kopczynski
President
Thomas Mitro
VP - Bus. Development
Craig Skenes
VP - Finance
Christopher Staten
VP - Human Resources
Kathleen McGinley
VP - Manufacturing
Kenneth Ruettimann
VP - R & D
Eric Carlson
VP - Regulatory Affairs
Marvin Garrett
Browse more venture capital transactions:
Prev: 10/10/2005: GlycoFi venture capital transaction
Next: 10/12/2005: Ophthonix venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs